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Abstract 
We aimed to verify if there is evidence to consider DCA, which inhibits the pyruvate 
dehydrogenase kinase (PDK) and reverts the metabolic shift of cancer cells from 
glycolysis to oxidative phosphorylation, as a promising drug for therapy of cutaneous 
melanoma (CM) patients. We assessed the expression profile of PDK 1, 2 and 3 in a 
series of melanoma samples, to verify if melanoma tumours express the DCA targets, if 
this expression correlates with the activation of important signalling cascades for 
melanomagenesis and also with the prognosis of melanoma patients. We also 
established the sensitivity of melanoma cell lines to DCA treatment, by assessing their 
metabolic alterations, proliferation and survival. 
We observed that both PDK 1 and 2 isoforms are overexpressed in CM compared to 
nevi, being this expression associated with the expression of the mTOR pathway 
effectors and independent of the BRAF mutational status. Melanoma cell lines treated 
with DCA showed a shift in metabolism, i.e. a decrease in glucose consumption and 
lactate production, downregulation of proliferation, an increase of apoptosis and a 
decrease in mTOR pathway activation. 
Our results suggest that PDK expression may play a role in melanoma development and 
that DCA can be useful for CM therapy, alone or in combination with mTOR inhibitors. 
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1. Introduction 
Cutaneous melanoma (CM) is a very aggressive malignancy, and despite being the least 
common type of skin cancer, it is responsible for the majority of skin cancer-related 
deaths. As the incidence of CM is rising, it is at present the most probable invasive 
cancer to develop before the age of 50 years in male gender [1, 2]. Exposure to UV 
radiation is considered the main risk factor for melanomagenesis [2]. CM can be 
classified in different histological subtypes, being the most common the superficial 
spreading melanoma (SSM), followed by nodular (NM), lentigo maligna (LMM) and 
acral lentiginous (ALM) melanoma. SSM and NM arise in skin with intermittent sun 
exposure, whereas LMM occurs in chronic sun-damaged skin and ALM is restricted to 
skin with no sun exposure. This histological classification has no prognostic value [3, 
4]. Staging of CM takes into account tumour thickness, ulceration, mitotic rate, node 
involvement and the presence of metastasis [5]. Fortunately, most cases of CM are 
diagnosed in an early stage, with a 5-year survival rate reaching 98% [1]. Nevertheless, 
for patients with metastatic melanoma the median survival is only 8-9 months [5]. 
CM is a very heterogeneous tumour and many cell signalling pathways are deregulated 
in melanomagenesis [6, 7]. The MAPK pathway is constitutively activated in the 
majority of CMs. NRAS mutations were reported in 10-20% of CMs, being NRASQ61K/R 
the most common. BRAF mutations, and in particular the BRAFV600E mutation, were 
identified in 40-60% of cases. Our group observed an association between the presence 
of BRAF mutations and the recently described TERT promoter mutations in CM [8]. 
BRAFV600E, and to a lesser extent, NRASQ61K/R mutations were also reported in almost 
80% of nevi (benign melanocytic lesions that are considered as precursors of CM in 
25% of the cases), indicating that the activation of the MAPK pathway may be 
necessary but not sufficient for melanoma development [7, 9, 10]. In fact, BRAFV600E 
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has been related to oncogene-induced senescence and therefore may lead, in many nevi, 
to a growth-arrest condition [11]. Activation of the PI3K-AKT-mTOR pathway may 
overcome this senescence phenotype and boost tumour progression [12]. Our group has 
confirmed the importance of the PI3K-AKT-mTOR pathway in CM aggressiveness by 
associating its activation with the presence of BRAF mutations and worse prognostic 
features. Indeed, overexpression of mTOR pathway effectors associated with higher 
mitotic rate, higher Clark level, increased tumour thickness and presence of skin 
ulceration [13]. 
Before 2011, treatment options for patients with advanced CM relied mainly on 
conventional chemotherapy, which had low response rates and minor effects in patients’ 
overall survival (OS). Ever since, five new drugs were approved for stage IV CM 
patients [14]. Ipilimumab, an anti-CTLA4 antibody, revealed marked improvements in 
OS of the patients, but its adverse effects turned it not suitable for all patients [15]. 
Vemurafenib and dabrafenib, selective inhibitors of BRAFV600E, and trametinib, a MEK 
inhibitor, all target the MAPK pathway and were reported to achieve response rates 
greater than 50%, even better than those for ipilimumab. However, their improvements 
in OS do not exceed 7-8 months due to the development of resistance [16-18]. Recently, 
another immune modulator, pembrolizumab, an antibody against the programmed death 
receptor-1 (PD-1), was approved for the treatment of patients with unresectable or 
metastatic melanoma and disease progression following ipilimumab or, if BRAFV600 
mutation positive, a BRAF inhibitor [19]. Clinical trials with drugs targeting the PI3K-
AKT-mTOR pathway are underway [4, 14], yet new therapeutic approaches are 
warranted. 
Cancer cell metabolism differs from that of normal cells. In normal cells, depending on 
O2 availability, glucose can be partially metabolized to lactate through glycolysis in 
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hypoxic conditions, or it can be fully oxidized to CO2 in the presence of O2, through 
mitochondrial oxidative phosphorylation, a more efficient energetic process. On the 
other hand, cancer cells metabolize most glucose to lactate, regardless of their O2 
supply, the so called “Warburg effect” [20, 21]. The acquisition of this glycolytic 
phenotype in cancer cells is not fully understood, still an essential role has been 
recognised for the transcription factor hypoxia-inducible factor 1α (HIF1-α) [22]. HIF1-
α protein is known to be stabilized under hypoxia, but oncogenic pathways, such as the 
MAPK and the mTOR pathways, also seem to mediate its activation in cancer (Fig. 1) 
[22, 23]. Strong evidence indicates that CM acquires this glycolytic phenotype, which 
can be confirmed by FDG-PET scanning of patients [24-27]. In fact, HIF1-α appears to 
be overexpressed in CM, because the skin is a mild-hypoxic environment and the 
production of melanin indirectly stimulates HIF1-α expression by ROS production [28-
30]. Yet, cytoplasmic glycolysis must be uncoupled from the mitochondrial oxidative 
phosphorylation, so that most pyruvate can be converted to lactate. This last process is 
driven by pyruvate dehydrogenase kinase (PDK), an enzyme upregulated by HIF1-α 
(Fig. 1) [31, 32]. 
PDK is an element of the mitochondrial pyruvate dehydrogenase complex (PDC). PDC 
comprises the pyruvate dehydrogenase (PDH) enzyme and its regulatory proteins: PDK 
that by phosphorylating PDH acts as an inhibitor, and pyruvate dehydrogenase 
phosphatase that activates PDH by dephosphorylation [33]. Dephosphorylated PDH 
catalyses the oxidative decarboxylation of pyruvate into acetyl-CoA, CO2 and NADH 
(H+), thereby linking the glycolytic pathway to the oxidative pathway of tricarboxylic 
acid cycle (Fig. 1) [33]. There are four isoforms of PDK (1, 2, 3, 4) which differ in their 
intrinsic activity, tissue distribution and sensitivity to their selective inhibitor drug, 
dichloroacetate (DCA) [33-35]. Although PDK1 is the only one able to bind to all PDH 
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phosphorylation sites, PDK3 appears to be the most active isoform [33]. PDK2 is the 
most sensitive to inhibition by DCA and is ubiquitously expressed in different human 
tissues, while the others are more tissue specific [33, 34]. PDK4 is essentially related to 
physiological metabolic flexibility and it is the only isoform not upregulated by HIF1-α 
[32, 36]. PDK isoforms expression has been evaluated in various types of cancer, 
namely head and neck squamous cell carcinoma (HNSCC) [37], colon cancer [38], renal 
cell carcinoma [39] and gastric cancer [40]. 
DCA has been used in the treatment of conditions associated with lactic acidosis in the 
setting of mitochondrial dysfunction, such as congenital mitochondrial diseases [35]. In 
non-small-cell lung, glioblastoma and breast cancer cells, Bonnet et al. reported that 
DCA induces apoptosis and decreases cell growth, by promoting glucose oxidation, 
mitochondrial membrane depolarization and ROS production [41]. These effects have 
been replicated in different cancer models and seem to be selective in cancer cells [35, 
41, 42]. Moreover, DCA is also able to suppress angiogenesis through indirect HIF1-α 
inhibition [43]. All these data combined with the well-known safety profile in humans, 
turn DCA into a promising drug for cancer therapy. A clinical trial to evaluate the effect 
of DCA in glioblastoma patients was already performed, reporting increased apoptosis 
and decreased angiogenesis, with promising results in four of five patients [44]. 
In the present study, PDK 1-3 isoforms expression in CM was assessed and its 
association with the expression of major signalling pathway cascades for 
melanomagenesis and with the prognosis of melanoma patients was evaluated. Also, in 
vitro studies were performed to assess the effect of DCA treatment in metabolism, 
proliferation and survival of melanoma cell lines with different genetic profiles. 
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2. Materials and Methods 
2.1 Sample selection, clinical-pathological and prognostic parameters 
Formalin-fixed, paraffin-embedded tissues from 120 CM cases and from 22 
melanocytic nevi (12 compound nevi and 10 Spitz nevi) were retrieved from the Service 
of Anatomic Pathology of the Hospital S. João, Porto, and of Hospital S. Marcos, 
Braga. Clinical-pathological (Table 1) and follow-up data were obtained from the 
patients’ records and the Oncology Registries of Hospital S. João and of Hospital S. 
Marcos, and from RORENO (Oncology Registry of North Region). All cases were 
revised and staged according to the 7th edition of AJCC [5]. Follow-up data includes the 
recurrences and metastases (DFS) (n=108) and the number of deaths due to melanoma 
(disease-specific mortality; OS) (n=118). The mean follow-up time of the patients for 
DFS was 51 months (SE±3.59, range 1–195) and for OS was 55 months (SE±3.48, 
range 1–207). This work was approved by the Local Ethical Committee and was in 
accordance to the National Ethical rules. 
 
2.2 Immunohistochemical analysis 
Staining for the proteins analysed was performed on 3-µm paraffin sections of 
representative tumour areas, and mounted on poly-L-lysine-coated slides, with the 
Envision G/2 System/AP (K5355; Dako, Denmark). Sections were deparaffinised and 
rehydrated, followed by a microwave antigen retrieval procedure with 10 mM sodium 
citrate buffer pH 6.0 with 1 mM EDTA pH 9.0 (PDK2), or EDTA buffer pH 9.0 (PDK1 
and PDK3). The sections were incubated overnight at 4°C in a humidified chamber with 
the primary antibodies PDK1 (polyclonal, rabbit, 1:50), PDK2 (polyclonal, rabbit, 
1:150), PDK3 (monoclonal, mouse, 1:500), all from Sigma-Aldrich Co. (St. Louis, 
Missouri, USA). The detection was obtained with the alkaline phosphatase anti-
8 
 
phosphatase method, and the colour was developed with permanent red chromogen. The 
slides were counterstained with haematoxylin, and then mounted using a water-miscible 
mounting medium. The alkaline phosphatase anti-phosphatase method was performed 
to avoid melanin pigmentation interference with immunohistochemistry analysis. 
Human stomach tissue was used as negative (omission of primary antibody) and 
positive control. 
 
2.3 Immunohistochemical evaluation 
Three observers (J.M.L., H.P. and R.C.) evaluated tumour cell immunoreactivity 
without the knowledge of any clinical data of the cases. Adjacent non-tumour tissue 
immunoreactivity was used as an internal control. An IHC score was settled for PDK1-
3, and results from the multiplication of the intensity score of the staining (negative=0, 
weak=1, moderate=2 and strong=3) and the extension score of the immunoreactivity of 
tumour cells (0-5%=0, 6-25%=1, 26-50%=2, 51-75%=3, 76-100%=4). IHC scores were 
then classified as negative/low (score value ≤4) and moderate/high (score value >4). 
Analysis of the MAPK and the PI3K-AKT-mTOR cascades in part of the series has 
been previously done [13] and the results were used in this study.  
 
2.4 DNA extraction and mutation analysis 
Extraction of DNA from tumours smaller than 5mm was performed after 
microdissection with PALM MicroLaser Systems (PALM, Germany) and using the 
Quiamp DNA micro kit (Quiagen, Hilden). In tumours larger than 5mm, DNA 
extraction was done by manual dissection of 10µm whole sections of paraffin-
embedded tissue using the Invisorb spin tissue mini kit (Invitek, Berlin). BRAF exon 15 
and NRAS exon 2 fragments were amplified by polymerase chain reaction (PCR) using 
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previously described primers [45]. Genomic DNA (25-100 ng) was amplified by PCR 
using the following cycling conditions: 35s at 94°C, 40s at 58°C for BRAF and 57°C 
for NRAS, and 45s at 72°C for 40 cycles. 
All PCR products were purified and directed sequenced on an ABI Prism 3130 xl 
Automatic sequencer (Perkin-Elmer, Foster City, CA) using the ABI Prism Dye 
Terminator Cycle sequencing Kit (Perkin-Elmer). The sequencing reaction was 
performed in the forward direction, and an independent PCR amplification, in the 
forward and reverse direction, was performed in samples suspected to carrier mutations. 
Again, BRAF and NRAS mutational analysis in part of the series has been previously 
done [13] and the results were used in this study. 
 
2.5 Cell lines and culture conditions 
Two cell lines were used in this work, A375 skin melanoma cell line, which harbours 
BRAFV600E and Mewo skin melanoma cell line that harbours BRAFwt. Both cell lines 
were tested for the presence of mycoplasma.  
A375 was maintained in RPMI medium (Gibco/BRL – Invitrogen) and Mewo was 
maintained in DMEM medium (Gibco/BRL – Invitrogen). All media were 
supplemented with 10% of fetal bovine serum, 100U/mL Penicillin and 100ug/mL 
Streptomycin. Cell lines were maintained in a humidified atmosphere (5% CO2) at 
37ºC. 
  
2.6 Treatment of melanoma cell lines with DCA  
Sodium dichloroacetate, purchased from Sigma-Aldrich (St. Louis, MO, EUA), was 
dissolved in dH2O and added to the culture medium and used for 24 and 48h treatment. 
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Melanoma cells incubated with culture medium supplemented with dH2O served as 
control. 
 
2.7 Cell viability assay 
The effects of DCA in melanoma cell lines growth was analysed by PrestoBlue (PB) 
assay. Cells were seeded in 96-well plates at a density of 5x103 in 200 µl medium. After 
24h, the medium was replaced by a medium containing 5, 20, 40, 60 mM of DCA. Cells 
were incubated for 24 and 48h, washed with PBS (pH 7.4) and assayed for cell growth 
using PB according to the manufacturer’s instructions. During incubation with the cells, 
PB reagent is modified by the reducing environment of the viable cells and becomes 
highly fluorescent. Fluorescence was measured using a microplate reader (Synergy HT 
Multi-Mode Microplate Reader, BioTek Instruments Inc., Winooski, VT, USA) at 
excitation and emission wavelengths of 560 and 590nm, respectively. The absorbance 
of the wells containing culture medium and tumour cells was used as control and each 
experimental condition was evaluated with triplicates and repeated in duplicate. By 
comparing the measured fluorescence/absorbance of the wells containing DCA with the 
measurements of the wells containing untreated cells, it was possible to generate dose-
response profiles and determine IC50 (the concentration that inhibits survival in 50%) 
values, using GraphPadPrism5.0 (GraphPad Software, Inc., La Jolla, CA). 
 
2.8 Glucose and lactate quantification 
For glucose and lactate levels measurements, melanoma cells were plated in 6-well 
plates at a final density of 2×105 cells/well and incubated at 37 °C for 24 h. Cells were 
then treated with 35mM of DCA. As controls, cells were incubated with the vehicle 
compound (dH2O). Following 24 and 48h of treatment, culture medium was collected. 
11 
 
Glucose levels present in the conditioned medium in culture were quantified using 
Glucose GOD/PAP Kit (Roche Applied Sciences) and subtracted to the initial levels (0 
hours). Lactate was quantified in a similar manner, using the LO-POD enzymatic 
colorimetric assay (Spinreact, Sant Esteve de Bas, Spain). 
 
2.9 Cell cycle and apoptosis analysis 
For cell cycle profile and apoptosis analysis, melanoma cells were plated in 6-well 
plates at a final density of 1×105 cells/well and incubated at 37 °C for 24 h. Cells were 
then treated with DCA at 35mM for 24 and 48h of treatment. As controls, cells were 
incubated with the vehicle compound (dH2O). For cell cycle analysis, cells were then 
harvested and fixed overnight in ice-cold 70% ethanol. Afterwards cells were 
resuspended in PBS with 0.1 mg/mL RNase A and 5 μg/mL propidium iodide, before 
analysis. For apoptosis measurements, cells were harvested and the levels of apoptosis 
were analysed by flow cytometry using the Annexin-V FITC Apoptosis Kit (Clontech 
Laboratories, Inc., Saint-Germain-en-Laye, France) according to the manufacturer’s 
instructions. Flow cytometry analysis of cellular DNA content and phosphatidylserine 
externalization was performed with a flow cytometer (BD Accuri C6), plotting at least 
20000 events per sample. The data was analysed using the FlowJo 7.6.5 software (Tree 
Star, Inc., Ashland, USA). 
 
2.10 Western blot analysis and antibodies 
Cells were lysed for 15 min at 4°C using RIPA buffer (1% NP-40 in 150 mM NaCl, 50 
mM Tris (pH 7.5), 2 mM EDTA) containing phosphatase and protease inhibitors. 
Proteins were quantified using a modified Bradford assay (Biorad). Protein samples (50 
µg) were separated in 10% SDS/PAGE gels and electroblotted to Hybond ECL 
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membrane (Amersham Biosciences). We used the following primary antibodies: PDH 
and pPDH Ser293, from Abcam; PDK1 (Sigma-Aldrich), PDK2 (Sigma-Aldrich), 
HIF1-α (Transduction Laboratories), and the mTOR pathway effectors phospho-S6 
Ser235/236, s6, phospho-4E-BP1 Thr37/46, 4EBP1, all from Cell Signaling 
Technology. Secondary antibodies were conjugated with peroxidase (Santa Cruz 
Biotechnology) and visualized by the ECL detection solution. Membranes were re-
stained with a goat polyclonal anti-actin (Santa Cruz Biotechnology) antibody for 
loading protein control. All experiments and quantifications (using Bio-Rad Quantity 
One 1-D Analysis software (4.6.6 version)) were performed in triplicate. 
 
2.11 Statistical analysis 
Statistical analyses were performed using STAT VIEW-J 5.0 (SAS Institute, Inc., Cary, 
NC). The relationship between the average expression level (score) of the 
immunohistochemistry markers and clinical-pathological parameters was evaluated by 
ANOVA. When appropriate, multiple comparison corrections were performed using the 
post hoc Bonferroni and Tamhane tests. The correlation between the immunoreactivity 
score of the different markers was assessed using the Fisher’s exact test. The data from 
the cell lines experiments was analysed by the two-tailed unpaired Student’s t-test. The 
Kaplan-Meier method and log-rank test were used to evaluate the melanoma survival 
data. Univariate and multivariate analyses were performed to determine the prognostic 
value of covariates regarding OS and DFS using the Cox regression model. OS and DFS 
were calculated from the time of diagnosis until death due to disease or metastasis, 
respectively, or censored at the time of the latest follow-up or death unrelated to the 
disease. A p value <0.05 was considered statistically significant. 
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3. Results 
3.1 Expression of PDKs in CM and nevi 
Both in CM and nevi lesions, PDK 1, 2 and 3 isoforms were expressed not only in 
melanocytes/melanoma cells, but also in keratinocytes and in the cells of sebaceous 
glands and hair follicles. The expression levels of all PDK isoforms analysed were 
positively correlated between them, suggesting a concomitant expression of these 
proteins (Table 2). 
3.1.1 PDK1 immunohistochemical expression 
Cytoplasmic PDK1 staining was observed in 88% of CM and 76% of nevi (Fig. 2A). 
Negative/low staining score was observed in 52% and 76% and moderate/high staining 
score was observed in 48% and 24% of melanomas and nevi, respectively. Therefore, 
cutaneous melanoma displayed significantly higher mean levels of PDK1 expression 
than nevi (p=0.03) (Fig. 2B). Regarding the histological subtypes of CM, LMM 
displayed greater PDK1expression levels than NM (p=0.04) and ALM (p=0.04). No 
association was found between the expression of PDK1 and type of sun exposure. With 
regard to the prognostic factors, PDK1 was more expressed in tumours ≤ 1 mm thick 
(p=0.02). Higher PDK1 expression levels were associated with lower tumour stages 
(p=0.04), but not with overall and disease-free survival of the patients. We also 
evaluated if the expression of PDK isoforms was related to the MAPK and the PI3K-
AKT-mTOR pathways. No association was found between the expression of PDK1 and 
BRAF/NRAS mutations or with the activation of the MAPK pathway (evaluated by 
pERK expression). PDK1 expression was positively correlated with the expression of 
proteins of the PI3K-AKT-mTOR cascade, namely mTOR and 4E-BP1 (p=0.02 and 
p=0.04, respectively). 
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3.1.2 PDK2 immunohistochemical expression 
PDK2 displayed both nuclear and cytoplasmic expression in 87% of CM and 83% of 
nevi (Fig. 2A). Negative/low staining score was observed in 58% and 89% and 
moderate/high staining score was observed in 42% and 11% of melanomas and nevi, 
respectively. The mean expression level of PDK2 was higher in CM compared to nevi 
(p<0.01) (Fig. 2B). With regard to the histological subtypes of CM, SSM exhibited 
higher levels of PDK2 expression than ALM (p=0.02). We did not find any association 
between type of sun exposure and the expression of PDK2. Lower tumour stages 
showed significantly higher levels of PDK2 (p=0.02), although no association was 
found between the expression of this isoform and the main prognostic factors of CM, 
neither with overall and disease-free survival of the patients. PDK2 expression was not 
associated with BRAF/NRAS mutational status or with the activation of the MAPK 
pathway. A significant positive correlation was found between PDK2 expression and 
AKT expression from the PI3K-AKT-mTOR cascade (p=0.03). 
3.1.3 PDK3 immunohistochemical expression 
PDK3 displayed cytoplasmic expression in all CM and nevi. Negative/low staining 
score was observed in 28% and 22% and moderate/high staining score was observed in 
72% and 78% of CM and nevi, respectively. The level of expression of PDK3 isoform 
was similar between CM and nevi (Fig. 2B). There were no significant differences when 
comparing the mean level of PDK3 expression between CM subtypes and the type of 
sun exposure. Tumours with thickness ≤ 1 mm and those with lower stages displayed 
higher levels of PDK3 (p=0.01 and p<0.01, respectively). Ulceration, mitotic rate and 
overall and disease-free survival of the patients were not significantly associated with 
PDK3 expression. No association was found between the expression of PDK3 and 
BRAF/NRAS mutations nor the activation of the MAPK cascade. Regarding the PI3K-
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AKT-mTOR pathway, PDK3 expression was positively correlated with total AKT, 
mTOR and 4E-BP1 expression (p<0.01, p<0.01 and p=0.04, respectively). Due to the 
general expression of PDK3 in every CM and nevi, the subsequent in vitro analysis did 
not include this PDK isoform. 
 
3.2 The effect of DCA treatment in melanoma cell lines viability 
A375 and Mewo melanoma cell lines were exposed to increasing concentrations of 
DCA to establish the effect on cell viability, using the PrestoBlue assay. DCA reduced 
the viability of both cell lines in a dose-dependent manner after 24 and 48h treatment, 
although A375 was slightly more sensitive to DCA treatment, with a higher growth 
inhibition when compared to Mewo cell line (Fig. 3). The effect of DCA on A375 cell 
viability was observed after treatment with 5mM and in Mewo cell line was more 
intense after 20mM treatment, with inhibition values ranging between 3 and 87% in 
A375 and 5 to 65% in Mewo. The IC50 values were estimated as 33±5.5mM for A375 
and 39.9±2.2mM for Mewo cell line, after 48h of DCA treatment (Fig. 3). 
 
3.3 The effect of DCA treatment in glucose consumption and lactate production 
levels of melanoma cell lines 
To evaluate the effect of DCA in the metabolism of melanoma cell lines, glucose and 
lactate levels were quantified in the culture medium after 24h and 48h treatment with 
35mM of DCA, a concentration near the IC50 for both cell lines. The consumption of 
glucose and the production of lactate decreased in both melanoma cell lines after 
treatment with DCA (Fig. 4). A375 and Mewo cell lines displayed a significant decrease 
in the glucose consumption level both after 24h and 48h of DCA treatment (p=0.01 and 
p˂0.01, respectively). The lactate production level was also significantly decreased after 
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24h and 48h in A375 (p=0.01 and p˂0.01, respectively) and in Mewo (p˂0.01) cell 
lines. 
 
3.4 The effect of DCA treatment in PDK and mTOR pathway effectors, and in 
HIF1-α expression in melanoma cell lines 
The efficacy of DCA treatment in inhibiting the PDK activity was evaluated by 
analysing the expression of the phosphorylated downstream effector PDH, by western 
blot. At 24h after DCA treatment, significantly inhibition of the phosphorylation of 
PDH in both cell lines was observed (p˂0.01) (Fig. 5). PDK1 and PDK2 expression was 
not altered by DCA treatment (Fig. 5), as expected. The expression of the two 
downstream effectors and readouts of mTOR pathway activation, S6 and 4EBP1 was 
also evaluated. Although DCA treatment did not alter S6 and 4EBP1 expression, the 
expression level of the phosphorylate forms of both proteins was decreased in A375 
(p=0.03 and not significant, respectively) and in Mewo (p˂0.01 and p=0.01, 
respectively) (Fig. 5). As DCA may affect HIF1-α levels, the expression of this protein 
was also evaluated, and no change was observed after DCA treatment (Fig. 5). Similar 
results were obtained at 48h after DCA treatment, which significantly inhibits 
phosphorylation of PDH in both cell lines (p˂0.01). The expression level of the 
phosphorylated forms of S6 and 4EBP1 was significantly decreased in A375 (p=0.01 
and p=0.02, respectively) and in Mewo (p=0.01 and not significant, respectively). The 
expression of PDK1, PDK2 and HIF1-α was not altered (data not shown). 
 
3.5 The effect of DCA treatment in cell cycle and apoptosis of melanoma cell lines  
To clarify the mechanism of action of DCA, cell cycle analysis and apoptosis 
measurements were performed in both cell lines, after 24 and 48h of treatment with 
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35mM of DCA. The cell cycle was analysed with propidium iodide. After 48h of DCA 
treatment, A375 cell line displayed a significant increase in the percentage of cells in 
the G0/G1 phase of the cell cycle (from 65.0±4.9% observed in non-treated cells to 
85.2±10.2% in DCA treated cells; p=0.04), a significant decrease in G2/M (from 
11.3±1.3% observed in non-treated cells to 5.2±2.2% in DCA treated cells; p=0.01) and 
a decrease, not reaching the threshold of statistical significance, in S phase (from 
19.7±1.8% observed in non-treated cells to 9.1±6.7% in DCA treated cells; p=0.06) 
(Fig. 6). The same tendency was observed in Mewo cell line at 48h after DCA treatment 
(increase in the percentage of cells in Go/G1, and decrease in S and G2/M) although not 
reaching statistical significance (Fig. 6). Flow cytometry analysis was carried out 
following Annexin V/Propidium iodide staining. A significant increase in the number of 
apoptotic cells in A375 cell line after 48h of DCA treatment was observed (3.0±0.5% in 
non-treated cells to 16.9±4.6% in DCA treated cells; p˂0.01) (Fig. 7). Non-significant 
increases in the percentage of apoptotic cells in A375 cell line after 24h and in Mewo 
cell line after 24h and 48h treatment with DCA were observed. 
 
 
4. Discussion 
In this work we established, for the first time, that cutaneous melanoma overexpresses 
PDK1 and PDK2 proteins. PDKs are key proteins, regulated by HIF1-α, driving 
malignant cells into the aerobic glycolysis phenotype, a hallmark of cancer [20, 22, 31]. 
The Warburg effect is considered a resistance factor to conventional chemotherapies 
[21]. The overexpression of PDK found in CM, lead us to evaluate the effect of DCA 
treatment in melanomas cell lines. We observed that DCA treatment decreases glucose 
consumption and lactate production in melanoma cell lines, consistent with the effect of 
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DCA in the shifting from aerobic glycolysis to oxidative phosphorylation previously 
reported in cancer cells [46]. This shift in the glucose metabolism probably results from 
the observed significant decrease in the expression of the phosphorylated form of PDH, 
which also confirms the efficacy of DCA treatment. It is relevant that the correct 
readout of DCA effect is the level of phosphorylated PDH, since by inhibiting PDK 
activity and not its expression, DCA stimulates PDH dephosphorylation (Fig. 1). 
We observed a dose-dependent decrease in cell viability after DCA treatment in both 
melanoma cell lines. Also, a downregulation of proliferation, through G0/G1 arrest, 
along with an increase in apoptosis was observed in both cell lines, but only statistically 
significant in A375 cell line. The fact that the concentration of DCA selected in the 
present study (35 mM) is slight below the IC50 for Mewo cell line may explain the less 
pronounced effect observed in those cells. 
The relationship between DCA and HIF-1α in cancer is not completely understood, as 
DCA increases tissue oxygen consumption and ROS production, which should lead to 
HIF-1α up-regulation or stabilization, respectively [47, 48]. Conversely, some authors 
reported that DCA leads to a decrease in HIF1-α expression [25, 49, 50]. In our work, 
no alteration was observed in HIF1-α level after DCA treatment of melanoma cell lines, 
concordant with Shahrzad et al. who reported that HIF1-α expression only decreases 
after DCA treatment in hypoxic conditions [50]. 
To overcome the mutant BRAF-induced senescence and to progress to more aggressive 
phenotypes, CM probably activates other signalling cascades, such as the mTOR 
pathway [12]. This pathway contributes to the Warburg effect by promoting HIF1-α 
activity, which in turn can increase PDK expression [23, 31]. We have previously 
reported a complete activation of this pathway in CM [13]. In the present study we 
observed a concomitant expression of PDK 1, 2 and 3 and of the mTOR pathway 
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effectors in cutaneous melanomas. The expression of the PDK isoforms in CM 
correlated positively with the expression of mTOR, as well as with upstream and 
downstream effectors of this pathway: AKT and 4E-BP1. Moreover, we observed a 
significant decrease in pS6 and p4EBP1 in A375 and Mewo cell lines after DCA 
treatment. 
Nevi share some genetic alterations with CM, as both present a high frequency of 
BRAF mutations [10]. Although in a much lower level, PDKs expression was also 
observed in nevi. We evaluated whether the BRAF mutational status and the 
downstream activation of ERK could be associated with a higher expression of PDK. 
We did not find any association in nevi nor in CM. A375 cell line harbour the 
BRAFV600E mutation and Mewo cell line is wild type for this gene and the response of 
both cells lines to DCA treatment was similar, despite with variable intensity. In fact, it 
was already reported that the BRAF mutational status does not alter the sensibility to 
DCA treatment [51]. These results contrast with our previous findings using mTOR 
pathways inhibitors in several melanoma-derived cell lines, where we found higher 
sensitivity to RAD001 treatment in the CM cell lines harbouring a BRAFV600E mutation 
[52]. 
PDK isoforms were expressed in the cytoplasm of the melanoma cells, thus supporting 
the well-known mitochondrial function of such isoforms [33]. Regarding PDK2, a 
nuclear expression was observed in the majority of the CM cases. This nuclear location 
has also been reported for PDK1 in HNSCC [37]. As far as we know, it remains to be 
clarified the role of PDK in the nucleus but, recently, a nuclear function was advanced 
for PDH, the PDK downstream effector. Sutendra et al. reported that PDH is involved 
in the nuclear formation of acetyl-CoA [53]. In response to growth factor stimulation, 
PDH and its phosphatase translocate from the mitochondria, where it is inhibited by 
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PDK, to the nucleus, but a nuclear location for PDK was not identified [53]. Yet, there 
is evidence that some glycolytic enzymes are engaged in other cellular functions besides 
the glycolysis, namely in transcriptional regulation [54]. Additional studies are 
necessary to clarify whether PDK plays also a nuclear function. 
In renal cell carcinoma, PDK1 expression was reported to decrease along tumour 
progression [39]. Concordantly, in our work, PDK was found to be more expressed in 
lower tumour stages, without influencing the overall and the disease-free survival of the 
melanoma patients. At variance, PDK overexpression was identified as a marker of 
tumour progression, poor prognosis and recurrence, in HNSCC and gastric cancer [37, 
40, 55]. Although our aim was not to explore the prognostic role of PDK in CM, our 
results suggest that PDKs in CM may play a more active role in melanoma development 
than in melanoma progression. We are aware that our series is mainly composed by 
primary CM, and that further studies in advanced (metastatic) melanoma will be 
necessary in order to clarify this issue. 
Our aim in the present study was to explore biomarkers for new therapeutic approaches 
in CM patients. Our results suggest a potential usefulness of DCA in the management of 
CM patients, in line with Abildgaard et al. who reported a decrease in ATP levels and 
melanoma growth using DCA treatment [51]. These authors also reported a synergistic 
combination between DCA and a BRAF inhibitor, vemurafenib [51]. Furthermore, our 
results show a concomitant expression of PDK and mTOR pathway effectors in CM and 
downregulation of mTOR pathway activity by DCA treatment. Considering the results 
of Hong et al. who reported a synergistic effect of the combination of DCA with a S6K1 
(mTOR pathway effector) inhibitor [56], it is tempting to speculate that a synergistic 
therapeutic effect may be achieved in CM using the combination of DCA with a direct 
mTOR inhibitor. 
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5. Conclusions 
We report for the first time the overexpression of PDK1 and 2 in CM in comparison to 
nevi. The expression of PDKs was found to be associated with the expression of mTOR 
pathway effectors and not related with the BRAF mutational status. DCA treatment 
leads to a shift in metabolism, downregulation of proliferation, increased apoptosis and 
decreased mTOR pathway activation in melanoma cell lines. Taking all these results 
together, we conclude that PDK expression may play a role in melanoma development 
and that its inhibition by DCA alone or in combination with direct mTOR inhibitors 
may benefit CM patients. 
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Table 1 – Clinical-pathological features of cutaneous melanomas. 
Clinical-pathological features  
Number of cases (n) 120 
Median age (±SD) 61.5±17.0 
Gender [n (%)]  
Female 68 (56.7) 
Male 52 (43.3) 
  
Sun exposure  
Absent 27 (22.7) 
Intermittent 72 (60.5) 
Chronic 20 (16.8) 
  
Histological subtype [n (%)]  
LMM 16 (13.3) 
ALM 24 (20.0) 
NM 19 (15.8) 
SSM 61 (50.8) 
  
Median thickness [mm] 3.7 (0-70) 
  
 Epidermal ulceration [n (%)]  
absent 79 (65.8) 
present 41 (34.2) 
  
Mitotic rate [n (%)]  
˂ 1/mm2 45 (37.5) 
≥ 1/mm2 75 (62.5) 
  
pT [n (%)]  
≤ pT2 62 (51.7) 
> pT2 58 (48.3) 
 
 
 
 
 
27 
 
Table 2 – Mean pyruvate dehydrogenase kinases (PDKs) expression and positive p 
value correlation found between all PDK isoforms in cutaneous melanomas tumours. 
Protein 
Mean expression 
level (±SD) 
Correlation (p value) 
PDK1 4.8±3.5 
˂0.01 
 
˂0.01 
PDK2 4.6±3.6 
˂0.01 
PDK3 7.0±3.2  
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Figure 1 – Schematic representation of pyruvate dehydrogenase kinase (PDK) 
interactions. PDK can be upregulated by HIF1-α, which in turn can be activated by 
mTOR and BRAF. PDK phosphorylates and inactivates pyruvate dehydrogenase 
enzyme (PDH) activity, whereas pyruvate dehydrogenase phosphatase (PDP) catalyses 
the reverse reaction. Activated PDH converts pyruvate in acetil-CoA and promotes 
tricarboxylic acid (TCA) cycle. By inhibiting PDK, DCA stimulates PDH and therefore 
increases the flux of pyruvate into the mitochondria, promoting glucose oxidation over 
glycolysis. 
 
Figure 2 – A) Representative microphotographs of PDK1 (a, b) and PDK2 (c, d) 
expression observed in cutaneous melanomas (a, c) and nevi (b, d). APAP×200 (a-d). B) 
Graphic representation of the mean expression levels of PDK1, 2 and 3 observed in 
cutaneous melanoma and nevi. The data are presented as mean±SD. * refers to 
significant (p<0.05) difference when comparing the protein expression level observed in 
cutaneous melanomas with the expression observed in nevi. 
 
Figure 3 – A) Graphic representation of the percentage of viable cells of A375 and 
Mewo melanoma cell lines treated with various concentrations of DCA for 24 and 48h, 
determined by Presto Blue assay. The grey line marks the IC50 values obtained that were 
estimated as 53±2.8mM for A375 after 24h of DCA treatment, and 33±5.5mM for A375 
and 39.9±2.2mM for Mewo, after 48h of DCA treatment. In Mewo cell line, growth 
inhibition was observed after 24h of DCA treatment, although it did not reach an IC50 
value. B, C) Column graphic representation of the percentage of viable cells of A375 
(B) and Mewo (C) melanoma cell lines treated with various concentrations of DCA for 
24 and 48h. The data are presented as mean±SD. * refers to significant (p<0.05) 
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difference when comparing cells treated with DCA for 24h or 48h compared to non-
treated cells.  
 
Figure 4 – Graphic representation of the glucose consumption (A, B) and lactate 
production (C, D) evaluation in A375 (A, C) and Mewo (B, D) cell lines in the medium 
of cells non-treated or treated with 35mM of DCA for 24 and 48h. The data are 
presented as mean±SD. * refers to significant (p<0.05) difference when comparing cells 
treated with 35mM of DCA for 24h or 48h compared to non-treated cells. 
 
Figure 5 – A) Representative western blot analysis of pPDH, PDH, PDK1, PDK2, HIF 
1-α, pS6, S6, p4EBP1 and 4EBP1 expression observed in the melanoma cell lines after 
35mM of DCA treatment for 24h compared to non-treated cells. B) Graphic 
representation of the mean fold change of activated protein expression observed. The 
data are presented as mean±SD. * refers to significant (p<0.05) difference when 
comparing cells treated with 35mM of DCA for 24h compared to non-treated cells. 
 
Figure 6 – Graphic representation of the cell cycle analysis of A375 (A, B) and Mewo 
(C, D) cells non-treated or treated with 35mM of DCA for 24h (A, C) and 48h (B, D), 
determined by Flow cytometry. The data are presented as mean±SD. * refers to 
significant (p<0.05) difference when comparing cells treated with 35mM of DCA for 
24h or 48h compared to non-treated cells. 
 
Figure 7 – Graphic representation of the percentage of apoptotic A375 (A) and Mewo 
(B) cells non-treated or treated with 35mM of DCA for 24 and 48h. The data are 
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presented as mean±SD. * refers to significant (p<0.05) difference when comparing cells 
treated with 35mM of DCA for 24h or 48h compared to non-treated cells. 
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Expert Opinion on Therapeutic Targets:  
Guidelines for Original Research  
 
1. Overview 
Expert Opinion on Therapeutic Targets (EOTT) is the premier journal dedicated to in-depth reports and reviews of 
the latest developments in the field of drug target discovery and validation. It is distinguished from other 
publications by its high quality authorship and expertly drafted articles, which are structured to incorporate the 
author's own expertise on the subject. The following document details the requirements for ‘Original Research’ 
submissions.  
 
1.1 Audience 
The audience consists of scientists, managers and decision makers in the pharmaceutical industry, academic 
researchers working in the field of molecular medicine and others closely involved in R&D. 
 
1.2 Scope 
In addition to review papers, technology evaluations and editorials, EOTT is also a medium for the publication of 
original research on recently identified novel molecular drug targets. 
 
Contributions are welcomed in the form of:  
 
 Target selection and validation studies 
 
 Basic mechanism of action studies for investigative and marketed drugs 
 
 In vivo and in vitro studies, animal models, screening, assays, knockout studies, gene expression/function 
studies 
 
Supplements are published and actively encouraged. These include both traditional free-standing and in-journal 
supplements based on symposia proceedings (or sponsored workshops and meetings), and specific areas. 
Enquiries from potential guest editors, meetings organizers and sponsors are welcomed. 
 
In addition, EOTT has a Correspondence section. We welcome the submission of any correspondence piece or 
letters regarding any article published in the journal since its launch. The Correspondence section of the journal 
presents an open arena for objective commentary, debate and lively discussion. 
 
For more information regarding a Supplement or for the submission of a Correspondence piece, please send an 
email to claire.attwood@informa.com  
 
1.3 Rapid Publication 
Publication in EOTT is driven entirely by editorial considerations and independent authoritative peer review. As 
part of the journal’s responsive approach to the publication of clinical evidence, we offer two prioritised modes of 
rapid publication and a third non-prioritised mode: 
• FastTrack: This offers the most highly prioritised service, with a submission to online publication timeline of 5–7 
weeks (subject to 1–2 week author revision following initial peer-review and prompt turnaround of proofs). There is 
a publication support fee for this, based on a charge of £550 / €625 / $850 per published page. This charge 
supports the ultra-swift processing of material and 20 downloads of the article via access-tokens. 
• Rapid Track: This prioritised service offers submission to online publication in 10–12 weeks and is subject to a 
publication support fee of £260 / €300 / $400 per page; 10 downloads of the article via access-tokens are provided 
for this service.  
• StandardTrack: This non-prioritised standard service provides submission to online publication up to 20 weeks; 
there are no publication support fees charged for this mode. 
 
EOTT welcomes contact with the Editorial Offices preceding formal submission and particularly encourages prior 
contact for FastTrack submissions where a particular publication deadline is desired. 
 
 
 
 
2. Submitting a manuscript 
All material should be prepared as detailed below. Please refer to the Submission Checklist at the end of this 
document and ensure that all criteria are met before submission. This will ensure timely publication of your article.   
 
Submissions should conform to the latest version of the Uniform Requirements for Manuscripts Submitted to 
Biomedical Journals, prepared by the International Committee of Medical Journal Editors (ICMJE: 
http://www.icmje.org/). Although it is recommended that authors read the entire Uniform Requirements document, 
in particular, authors and contributors are referred to the following sections/paragraphs of this document: 
II A.1 and II A.2. – Notes defining and distinguishing authorship and contributorship.  
II .D.1. – Peer review 
II. E.1. – Patients and study participants 
II.F – Protection of human subjects in research 
IV.A.3 – Conflict of interest notification 
  
Please submit manuscripts in Microsoft Word (double spaced, Times New Roman, 12 pt) using the Manuscript 
Central online submission system (http://mc.manuscriptcentral.com/eott). As the peer reviewers will be blinded to the 
identity of the authors, contributors MUST provide a copy of the manuscript containing no author names or 
affiliations. These details should be provided on a separate cover sheet. Pages must be numbered.  
 
Authors sending incomplete submissions may be asked to rectify and resubmit the paper in case of any omissions 
or serious failures to follow the journal style. 
 
Prior publication: EOTT will only consider work that has not been previously published in full. Abstract, poster or 
oral presentations do not constitute prior publication, but should be mentioned in the covering letter and details 
included as a footnote on the manuscript title page. 
 
Trial registration: EOTT does not require trial registration as a condition for publication. However, as per the 
ICMJE requirements, if a study that is the subject of the manuscript has been registered, this should be mentioned 
in the covering letter and trial registration information included at the end of the Abstract; publication of a trial 
registry summary should be also be mentioned on the manuscript title page and the details provided as a 
reference citation. 
In the instance where preclinical research/work with animal subjects is included within the original research 
submission, contributors are required to follow the procedures in force in their countries which govern the ethics of 
work done with human or animal subjects. The Code of Ethics of the World Medical Association (Declaration of 
Helsinki) represents a minimal requirement. In particular: 
When experimental animals are used, state the species, strain, number used, and other pertinent descriptive 
characteristics.  
When describing surgical procedures on animals, identify the pre anaesthetic and anaesthetic agents used and 
state the amount of concentration and the route and frequency of administration for each. The use of paralytic 
agents, such as curare or succinylcholine, is not an acceptable substitute for anaesthetics. For other invasive 
procedures on animals, report the analgesic or tranquilizing drugs used; if none were used, provide justification for 
such exclusion.  
When reporting studies on unanaesthetized animals or on humans, indicate that the procedures followed were in 
accordance with institutional guidelines. 
 
3. Correspondence relating to the submission of papers 
All manuscripts must be accompanied by a covering letter and an electronic version of the Disclosure Form signed 
by the principal author(s). The covering letter should include all of the following information: 
 
 The name and contact details (telephone, fax, postal and email addresses) of the corresponding author 
who will deal with the comments from reviewers and approve final proofs. 
 A statement that the contribution represents original work that has not been previously published or 
simultaneously submitted for publication elsewhere.  
 A statement that the manuscript has been read and approved by all the authors, and that all the conditions 
as previously stated by the ICMJE have been met.  
 The body providing explicit ethical approval of the work reported should also be stated. 
 A statement of financial or other relationships of a declarable nature (i.e., commercial associations that 
might lead to a conflict of interest), including disclosure of sources of support in the form of sponsorship, 
grants, materials (drugs) or equipment, and editorial or manuscript support (see also Acknowledgements 
under Section 4.2). In case there are no disclosures of a declarable nature, or acknowledgements for 
financial or editorial support, this should be clearly stated. 
 The authors’ preference for publication with either English (UK) or US spellings. 
 
Please note that manuscripts without a covering letter or a Disclosure Form will not be considered to be ‘complete’ 
submissions. All complete submissions will be acknowledged by the Editorial Office upon receipt. 
 
4. Manuscript content 
4.1 General 
 
Manuscripts submitted should be in English and written for an international, general medicine readership. Where 
national or regional issues are discussed, the international context should also be considered. When a licensed 
drug or device is being discussed outside its licensed indication, this must be made clear to the reader.  
 
Manuscripts should be double-spaced with numbered pages. Keep the layout as simple as possible – it will be set 
to house style during the production process. 
 
4.2 Every article must contain: 
 
 Title page: All articles should have a concise, informative title that contains no brand names (no more 
than 50 words). In addition to the title itself, the title page should also have the name(s) and initials of all 
the authors and their institutional affiliation(s). The name of the corresponding author and their mailing 
address should be given in full, including email, telephone and fax numbers. Should any of the material 
contained in the paper have been previously presented at a meeting, the full name, location and inclusive 
dates of the meeting should also appear on the title page. Authors are to avoid using Trade names in their 
titles, and are encouraged to have non-promotional titles for their articles. 
 
 Abstract: The second page should contain a brief, structured abstract of the paper (no more than 200 
words) summarizing the main facts, findings and principal conclusions. Suggested headings: Objective 
(including the reason for the study); Research design and methods (including study population and setting, 
study blinding, comparators, dosage, treatment regimens and durations, efficacy and safety issues); Main 
outcome measures; Results (both efficacy results and adverse events should be given); Conclusions 
(qualified by any key limitations). No references are to be cited in the Abstract. Please bear in mind that 
the Abstract needs to accurately reflect the content of the article and that the aim of the Abstract is to draw 
in the interested reader. 
 
 Keywords: 4–6 keywords, listed in alphabetical order, are required to assist indexers in cross-referencing. 
The keywords will encompass the therapeutic area, mechanism(s) of action, key compounds and so on. 
 
 Body of the article: This should include the following sections: introduction; patients and methods; 
results; discussion; conclusions (see section 5 for organization of content). 
 
 Acknowledgements: This must include any declaration of interest by the authors (see also Section 3: 
Correspondence), including grants, fellowships or any commercial assistance or financial sponsorship 
received. It should also list any affiliation(s), organization(s) or entity(ies) that are relevant to the work 
reported. Some or all of this information may be published at the discretion of the Editor. Any contributions 
to the research, data analysis or assistance in manuscript preparation must also be acknowledged in this 
section. Finally, if any trial registration information and/or a trial registration number are available for the 
study, this should also be mentioned in the acknowledgements section.  
 
 References: Full references to relevant material cited in the text should be provided (see Reference style 
in Section 9 below). References should be comprehensive, accurate and up-to-date: wherever possible, 
please use primary references, and as far as possible, avoid the use of unpublished references (such as 
‘Data on file’ or ‘Poster’). 
 
5. Organization of content 
5.1 General 
 
Keep all formatting to a minimum and avoid assigning ‘styles’ to headings, extracts or paragraphs. Make sure that 
the ‘normal’ style is used throughout the text. Turn off the automatic hyphenation feature. Please use double-line 
spacing throughout the manuscript. Headings and sub-headings should be used to provide structure to the text 
with numbers (Arabic numerals) to indicate a hierarchy of the headings/sub-headings (i.e., 1.0, 1.1, 2.0, 2.1, 2.1.1, 
2.1.2 and so on).  
 
5.2 Units and symbols 
Use SI units where possible. Non-SI units should be accompanied by SI equivalents, for example, LDL-C < 70 
mg/dl (1.8 mmol/l). To indicate atom positions in a molecule, use the convention C-1, C-2 and so on. 
 
5.3 Spelling  
Manuscripts may be submitted in either US or UK English and will be published using the version of English used 
in the manuscript submitted to the Editor. All accepted manuscripts will be copyedited in house upon acceptance, 
but authors are advised to check their work for English spelling and grammar prior to submission. The Editorial 
Office can arrange an English language edit prior to submission if required - please contact the editorial 
office for details of available services and costs.  
 
5.4 Abbreviations  
Abbreviations should be defined on their first appearance both in the Abstract and in the text; commonly used 
abbreviations need not be defined. Authors are encouraged to submit a list of abbreviations used to the Editorial 
Office alongside the manuscript. Only underline or italicize words and letters that are required to appear in italics.  
 
5.5 Introduction  
This should state the clinical relevance and background to the study, its rationale and purpose. 
 
5.6 Patients (where appropriate) and experimental methods 
Authors should be as concise as possible about the experimental methods used. Should this concern human 
studies, this should contain details of the study population and setting, subject selection (inclusion/exclusion 
criteria), methods of randomization and blinding, and efficacy and safety measures. The study design and 
statistical methodology should be described, with justification for the choice of analysis and sample size given; 
CONSORT guidelines (www.consort-statement.org) should be considered where appropriate. All materials should 
be identified precisely, with drugs referred to by their generic names (proprietary names, if required, should be 
given in parentheses along with the company name and country of the manufacturer), and with dose and routes of 
administration. The ethical approval procedure followed and the name of the ethics committee should be stated. 
Indicate how adverse events were determined (and by whom) and indicate if/how compliance was measured. 
(Authors are reminded to ensure that they follow the ICMJE requirements when dealing with privacy and informed 
consent from patients – see Section II.E.1.of the ICMJE requirements document http://www.icmje.org/#privacy). 
 
5.7 Results  
Use should be made of tables and figures to help with the clear presentation of results data. The sample size of 
each data point should be shown, with p-values and confidence intervals quoted for significant findings. Any data 
not included in the analysis (including patients withdrawn from the study) should be detailed. Details of data on 
efficacy and adverse events should be provided in a balanced fashion. 
 
5.8 Discussion  
This will essentially be a discussion of the results and experimental data collected. The section should include 
implications of the findings and their limitations, with reference to all other relevant studies and the possibilities 
these suggest for future research. In addition, the discussion affords authors the opportunity to discuss the 
developments that are likely to be important in the future and the avenues of research likely to become exciting as 
further studies yield more detailed results.  
 
5.9 Conclusions  
This section must summarize the paper, with a concise statement of the clinical implications of the study results. 
Ensure that extrapolations are reasonable and that conclusions are justified by the data presented. Indicate if the 
study design can be generalized to a broader patient population. 
 
6. Tables 
Each table (with a brief, comprehensive title/header) should be presented in cellular format (rather than a simple 
tabbed form) on a separate page, at the end of the text. Tables should be numbered with Arabic numerals (Table 
1, Table 2….) and each table should be followed by a footnote where necessary. Define in the footnotes all 
abbreviations that are used in the table. Be sure that each table is cited in the text (but not within any section 
headings) and number tables consecutively in the order of their first citation in the text. In case data from another 
published or unpublished source is being used, please obtain permission and acknowledge the source(s). 
 
7. Figures & Structures 
Do include illustrations (figures/diagrams/structures) as appropriate. Please ensure that the following 
recommendations are adhered to as closely as possible:  
 Provide editable, electronic copies if possible; otherwise, please ensure that the camera-ready copy is of 
the highest resolution available.  
 Please submit figures as eps, illustrator, jpeg, ISISdraw or ChemDraw format. If these formats are not 
possible, figures can be submitted in PowerPoint or Word as a last resort.  
 Figures should employ CMYK rather than RGB color scheme.  
 Small figures should be 300 dpi and large figures should be 72 dpi.  
 Please note that we cannot improve resolution beyond that of the file submitted. 
 Figures and structures should be in separate files to the text. It is unnecessary to incorporate the figures 
into the body of the manuscript. If there are several figures, please submit these individually, rather than 
as one file (preferably the original source files).  
 Ensure that titles and figure legends/captions are included on a fresh page at the end of the manuscript. 
Legends (and labeling) should be based on the ‘stand-alone concept’, so that looking at the tables and 
figures conveys an immediate, clear message without needing to refer to the text. Define in the legend(s) 
all abbreviations that are used in the figure(s). 
 Figures should be numbered consecutively according to the order in which they have been first cited in the 
text.  
 If a figure has been previously published, acknowledge the original source and please submit written 
permission from the copyright holder to reproduce the material.  
 Colour figures will only be accepted if colour is deemed to be essential, at the discretion of the Editor-in-
Chief and Publisher. Use of colour in the printed journal will entail a charge on a scale related to the 
additional costs of colour reproduction.   
 Please submit chemical structures drawn in ISISDraw or Chemdraw and ensure that you submit these in 
their original, editable formats. Always indicate stereochemistry, and where necessary, use the wedge and 
hash bond convention for chiral centres and mark cis/trans bonds as such. 
 
The Editorial Office can arrange for figure re-drawing and medical illustration - please contact us for 
details of available services and costs.  
 
8. Companies and drug proprietary names 
 Companies are treated as single entities requiring a verb in the third person singular (e.g., GSK is 
developing an AII antagonist).  
 
 All medical substances should be referred to by their Recommended International Non-Proprietary Name 
(rINN). Proprietary or individual company trade names should only be mentioned where absolutely 
essential, for clarity, as in the case of combination products, or to avoid confusion, for example, between 
different formulations.  
 
 Drug brand names should not appear in paper titles.  
 
 In the body of an article, if it is necessary to use a brand name, when referring to a lead compound (or 
compounds claimed in patents) for the first time, please ensure that the ® or TM symbols are used as 
required, and that the name of the relevant company is also stated. Generic names always take a lower 
case first letter unless they are beginning a new sentence. 
9.  References 
Please ensure that all key work relevant to the topic under discussion is cited in the text and listed in the 
bibliography. Where relevant, do reference patents and websites as well. Reference to unpublished data should be 
kept to a minimum and authors must obtain a signed letter of permission from cited persons to use unpublished 
results or personal communications in the manuscript. 
9.1   Numbering 
References MUST be numbered consecutively, using Arabic numerals in square brackets, in the order in which 
they are first mentioned in the text. The reference list should appear in the same sequence as the numbers in the 
text.  
9.2  Annotations 
Papers or patents of particular interest should be identified using one or two asterisk symbols (• = of interest, •• = 
of considerable interest), and annotated with a brief sentence explaining why the reference is considered to be of 
interest. 
9.3 Bibliography 
References can be formatted using EndNote or Reference Manager according to the style of Current Medical 
Research and Opinion. 
References use plain, unformatted text, as in the following examples:  
 
Journals: 
1. Weissman P, Goldstein BJ, Rosenstock J, et al. Effects of rosiglitazone added to submaximal doses of 
metformin compared with dose escalation of metformin in type 2 diabetes: the EMPIRE Study. Curr Med Res 
Opin 2004;21:2029-35  
Books: 
2. Gottman J. Time Series Analysis. Cambridge: CUP, 1981  
Working party reports and similar: 
3. Clinical Disputes Forum Working Party. Pre-action protocol for the resolution of clinical disputes. London: 
Clinical Disputes Forum, 1998 
Pre-publication articles assigned DOI numbers: 
4. de Lau LM, Koudstaal PJ, Hofman A, Breteler MM. Subjective complaints precede Parkinson disease: the 
Rotterdam study. Arch Neurol 2006: published online 9 January 2006, doi:10.1001/archneur.63.3.noc50312  
Internet articles and website information: 
5. Suicidality in adults being treated with antidepressant medications. FDA Public Health Advisory. Washington, 
DC: FDA/Center for Drug Evaluation and Research, 2005. Available at: 
www.fda.gov/cder/drug/advisory/SSRI200507.htm [Last accessed 3 January 2006] 
Patents: 
6. Basf AG. Means and methods for preventing and treating caries. WO2006027265 (2006) 
Use the following formats for patent numbers issued by the World, US and European patent offices, respectively: 
WO0113324; US6803189; EP1549318 
 
Note, for citations with four or fewer authors/assignees, cite all names; for citations with more than four authors, 
cite three author names plus et al. 
 
Full reference details must be provided in the bibliography (for example, for journal citations, author surnames and 
initials, article title, journal name, year, volume, page range). Failure to do so may lead to a delay in publication or 
a return of the paper by the Editor to the author. 
 
10. Copyright assignment and disclosure 
Papers are published on the understanding that their copyright is assigned to the Publisher (Informa UK Ltd) once 
they are accepted for publication. If any material used is subject to third-party copyright, copyright clearance is the 
sole responsibility of the authors and must be supplied in writing to the Publisher.  
 
It is the responsibility of authors to disclose any affiliation with any organisation with a financial interest, direct or 
indirect, in the subject matter or materials discussed in the manuscript (such as consultancies, employment, expert 
testimony, honoraria, speakers bureaus, retainers, stock options or ownership) that may affect the conduct or 
reporting of the work submitted. If uncertain as to what might be considered a potential conflict of interest, authors 
should err on the side of full disclosure. Information about potential conflict of interest may be made available to 
reviewers and may be published with the manuscript at the discretion of the Editor.  
 
Corresponding authors will be sent a Copyright Form to sign on acceptance of their paper. The Disclosure Form 
(see end of this document) MUST be submitted on first submission of the article in order to be considered for peer 
review. This form would serve as a signed guarantee that:  
1. The manuscript submitted represents original work and has not been previously published or simultaneously 
submitted elsewhere for publication.  
2. Conditions as previously stated by the ICMJE; http://www.icmje.org have been met, and the body providing 
explicit ethical approval of the work reported has been stated in the manuscript. 
3. Trial registration information and a trial registration number (if available) for the study is mentioned in the 
Acknowledgements section.  
3. The manuscript has been read and approved by all authors. 
4. Any potential conflicts of interest and sources of funding are disclosed, ethical approval for the study has been 
obtained and that any sources of contributory support (bio statisticians, medical writers and so on) in the 
preparation of the manuscript are acknowledged. 
 
Please note that on acceptance of a manuscript, authors are required to send a hard copy of their article to Expert 
Opinion on Therapeutic Targets, 5th Floor, Telephone House, 69-77 Paul Street, London, EC2A 4LQ, UK. 
 
10.1 NIH/Wellcome-funded research 
Regarding articles that are funded by the NIH and the Wellcome trust: we allow authors to deposit the POST-print 
manuscript (peer-reviewed and revised, formally-accepted version) on Pub Med Central (PMC). Note that the 
POST-print version is not the Publisher’s final PDF. 
Depositing the final, accepted manuscript on PMC will be the authors’ responsibility, and will need to be done via 
the NIH Manuscript Submission System (NIHMS). Some steps on how to deposit your manuscript are listed under 
NIH’s ‘Method C’ here. Publicly funded articles can be deposited by authors on the PMC site immediately on 
receipt of formal acceptance of the manuscript. When prompted about the number of months after publication 
when the manuscript may become publicly available in PMC, select 12 months for NIH-funded work and 6 months 
for research funded by the Wellcome Trust. 
 
11. Proofs and publication 
Proofs in the form of Adobe Acrobat PDF files will be sent to the corresponding author via email for checking. If, 
because of delays, time is limited, the Publisher reserves the right to have proofs checked against original 
manuscripts by editorial staff or medical advisers. No major alterations to text will be accepted at proof stage. 
Electronic publication online will constitute formal publication of the article, with all subsequent critical changes or 
error correction being dealt with via publication of a formal Erratum or Corrigendum.  
12. Editorial support services 
The Editorial Office is available to advise authors throughout the writing and submission process. If required, we 
can also arrange for professional medical writing and illustration assistance, including: 
 Pre-submission language editing 
 Comprehensive re-formatting 
 Detailed technical editing 
 Figure redrawing 
 Medical illustration 
 
If you are interested in the above services, please contact the Editorial Office for further details and costs . 
Please note, these services are independent of the peer review process and undertaking such work does not 
guarantee final acceptance of the manuscript. 
 
13. Submission checklist 
Please use the checklist below to help prepare your submission or resubmission. It will help us to swiftly process 
your manuscript through production and avoid any unnecessary delays at a later stage.  
If you have any queries, please feel free to contact: 
 
Claire Attwood,  
Expert Opinion,  
1–2 Bolt Court, 
EC4A 3DQ, UK.  
Tel:. +44 (0)20 7017 7793 
Fax: +44 (0)20 7017 7667 
Email: Claire.Attwood@informa.com     
 
1. Manuscripts submitted online at http://mc.manuscriptcentral.com/eott 
 Include: i) covering letter uploaded as ‘file not for review’, ii) completed Disclosure Form, iii) attachment of 
the Original Research article (containing no author details) (in MS Word, double spaced, Times New 
Roman, 12 pt, pages numbered) and iv) any separately attached image files. 
 
2. Cover letter includes: 
a) Name and contact details of all authors, including corresponding author. 
b) A statement that the contribution represents original work, has not been previously published or 
simultaneously submitted for publication, that the manuscript has been read and approved by all 
authors, and that all the conditions as previously stated by the ICMJE have been met. 
c) A statement of financial or other relationships of a declarable nature. 
 
3. A structured abstract is provided.  
4. Four to six keywords are provided. 
5. Section headings follow EOTT style and all articles contain: Introduction; Methods; Results; Discussion 
and Conclusion (see Author guidelines: Section 5). 
6. No propriety drug names or brand names are used (or, these are used only when absolutely necessary, 
with a ® or TM sign and the company name included along with the first appearance of the trade name).  
7. An Acknowledgment section includes any declaration of interest by the authors, including grants, 
fellowships, or any commercial assistance or financial sponsorship received or of any affiliation, 
organization or entity which is relevant to the work reported. Any contributions to the research, data 
analysis or assistance in manuscript preparation should also be acknowledged in this section.  
8. References follow EOTT style (Author guidelines: Section 9). Reference annotations are present in the 
reference list. 
9. All figures and tables cited in the text are supplied. No figures or tables appear without being cited in the 
text. 
10. Tables are in cellular format, appearing at the end of the manuscript (following the references) 
11. All figures are supplied as editable, separate files with the legends appearing on a fresh page at the end of 
the manuscript. 
 
14. Editorial support services 
The Editorial Office is available to advise authors throughout the writing and submission process. If required, we 
can also arrange for professional medical writing and illustration assistance, including:  
 Pre-submission language editing 
 Comprehensive re-formatting 
 Detailed technical editing 
 Figure redrawing 
 Medical illustration  
 
If you are interested in the above services, please contact the Editorial Office for further details and costs. 
Please note, these services are independent of the peer review process and undertaking such work does not 
guarantee final acceptance of the manuscript. 
 
